However, direct clinical evidence supporting CXCR4 antagonists in CTCL remains limited, and translation will require a careful evaluation of efficacy, patient selection, and potential on-target effects given the broad physiological roles of CXCR4. This evidence concerns the gene CXCR4 and primary cutaneous T-cell non-Hodgkin lymphoma.